Abstract
Objective: Tourette's syndrome is polygenic and highly heritable. Genome-wide association study (GWAS) approaches are useful for interrogating the genetic architecture and determinants of Tourette's syndrome and other tic disorders. The authors conducted a GWAS meta-analysis and probed aggregated Tourette's syndrome polygenic risk to test whether Tourette's and related tic disorders have an underlying shared genetic etiology and whether Tourette's polygenic risk scores correlate with worst-ever tic severity and may represent a potential predictor of disease severity. Methods: GWAS meta-analysis, gene-based association, and genetic enrichment analyses were conducted in 4,819 Tourette's syndrome case subjects and 9,488 control subjects. Replication of top loci was conducted in an independent population-based sample (706 case subjects, 6,068 control subjects). Relationships between Tourette's polygenic risk scores (PRSs), other tic disorders, ascertainment, and tic severity were examined. Results: GWAS and gene-based analyses identified one genome-wide significant locus within FLT3 on chromosome 13, rs2504235, although this association was not replicated in the population-based sample. Genetic variants spanning evolutionarily conserved regions significantly explained 92.4% of Tourette's syndrome heritability. Tourette's-associated genes were significantly preferentially expressed in dorsolateral prefrontal cortex. Tourette's PRS significantly predicted both Tourette's syndrome and tic spectrum disorders status in the population-based sample. Tourette's PRS also significantly correlated with worst-ever tic severity and was higher in case subjects with a family history of tics than in simplex case subjects. Conclusions: Modulation of gene expression through noncoding variants, particularly within cortico-striatal circuits, is implicated as a fundamental mechanism in Tourette's syndrome pathogenesis. At a genetic level, tic disorders represent a continuous spectrum of disease, supporting the unification of Tourette's syndrome and other tic disorders in future diagnostic schemata. Tourette's PRSs derived from sufficiently large samples may be useful in the future for predicting conversion of transient tics to chronic tic disorders, as well as tic persistence and lifetime tic severity.
Original language | English (US) |
---|---|
Pages (from-to) | 217-227 |
Number of pages | 11 |
Journal | American Journal of Psychiatry |
Volume | 176 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2019 |
ASJC Scopus subject areas
- Psychiatry and Mental health
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Interrogating the genetic determinants of Tourette's syndrome and other tiC disorders through genome-wide association studies'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Psychiatry, Vol. 176, No. 3, 01.03.2019, p. 217-227.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Interrogating the genetic determinants of Tourette's syndrome and other tiC disorders through genome-wide association studies
AU - Tourette Association of America International Consortium for Genetics
AU - Gilles de la Tourette GWAS Replication Initiative
AU - Tourette International Collaborative Genetics Study
AU - Psychiatric Genomics Consortium Tourette Syndrome Working Group
AU - Yu, Dongmei
AU - Sul, Jae Hoon
AU - Tsetsos, Fotis
AU - Nawaz, Muhammad S.
AU - Huang, Alden Y.
AU - Zelaya, Ivette
AU - Illmann, Cornelia
AU - Osiecki, Lisa
AU - Darrow, Sabrina M.
AU - Hirschtritt, Matthew E.
AU - Greenberg, Erica
AU - Muller-Vahl, Kirsten R.
AU - Stuhrmann, Manfred
AU - Dion, Yves
AU - Rouleau, Guy
AU - Aschauer, Harald
AU - Stamenkovic, Mara
AU - Schlögelhofer, Monika
AU - Sandor, Paul
AU - Barr, Cathy L.
AU - Grados, Marco
AU - Singer, Harvey S.
AU - Nöthen, Markus M.
AU - Hebebrand, Johannes
AU - Hinney, Anke
AU - King, Robert A.
AU - Fernandez, Thomas V.
AU - Barta, Csaba
AU - Tarnok, Zsanett
AU - Nagy, Peter
AU - Depienne, Christel
AU - Worbe, Yulia
AU - Hartmann, Andreas
AU - Budman, Cathy L.
AU - Rizzo, Renata
AU - Lyon, Gholson J.
AU - McMahon, William M.
AU - Batterson, James R.
AU - Cath, Danielle C.
AU - Malaty, Irene A.
AU - Okun, Michael S.
AU - Berlin, Cheston
AU - Woods, Douglas W.
AU - Lee, Paul C.
AU - Jankovic, Joseph
AU - Robertson, Mary M.
AU - Gilbert, Donald L.
AU - Brown, Lawrence W.
AU - Coffey, Barbara J.
AU - Barzilai, Nir
N1 - Funding Information: Prothena Biosciences, Parexel, Revance Therapeutics, Retrophin, and Teva; he has received royalties from Cambridge, Elsevier, Future Science Group,HodderArnold,Medlink:Neurology,LippincottWilliams&Wilkins, and Wiley-Blackwell; and he serves on the editorial boards of Expert Review of Neurotherapeutics, Medlink, Neurology in Clinical Practice, the Botulinum Journal, PeerJ, Therapeutic Advances in Neurological Disorders, Neurotherapeutics, Tremor and Other Hyperkinetic Movements, and the Journal of Parkinson’s Disease. Dr. Coffey is on the scientific advisory boards of Abide Therapeutics and Genco Sciences; she receives honoraria from the American Academy of Child and Adolescent Psychiatry; she receives research support from Catalyst Pharmaceuticals, Neurocrine Biosciences, NIMH/UCSF, Otsuka, and Shire; she is on the scientific advisory boards of and receives research support from Auspex, Teva, and Nuvelution; and she is a co-chair and on the medical advisory board of the TAA, TAA-CDC Partnership. Dr. Kuperman is involved with Neurocrine for the purpose of recruiting a small number of individuals with Tourette syndrome for enrollment in a drug trial for a new medication to treat severe Tourette’s syndrome. Dr. Wagner has received a nonprofit grant from the German Research Foundation. Dr. Smoller is an unpaid member of the Bipolar/Depression Research Community Advisory Panel of 23andMe. Dr. Buckner has served as a consultant for Roche. Dr. Willsey has served as a consultant for Daiichi Sankyo. Dr. Heiman has received funding from the New Jersey Center for Tourette Syndrome and Associated Disorders. Dr.NealeisamemberofthescientificadvisoryboardforDeepGenomics and serves as a consultant for Avanir, Camp4 Therapeutics, and Merck. Dr. Mathews has received research support, honoraria, and travel support from the TAA and is a co-chair of the TAA scientific advisory board. Dr. Scharf has received consulting fees from Nuvelution Pharma and Abide Pharmaceuticals; he has received travel and grant support from the TAA and the TLC Foundation for Body-Focused Repetitive Behaviors; and he is a member of the scientific advisory boards for the TAA and the TLC Foundation for Body-Focused Repetitive Behaviors. The other authors report no financial relationships with commercial interests. Funding Information: Supported by NIH grants U01 NS040024 to Drs. Pauls, Mathews, and Scharf and the Tourette Association of America International Consortium for Genetics, NIH grants K23 MH085057 and K02 NS085048 and ARRA grant NS040024-09S1 to Dr. Scharf, NIH grant NS016648 and ARRA grant NS040024-07S1 to Dr. Pauls, grant MH096767 to Dr. Mathews, National Institute of Neurological Disorders and Stroke (NINDS) Informatics Center for Neurogenetics and Neurogenomics grant P30 NS062691 to Drs. Coppola and Freimer, and grants from the Tourette Association of America to Drs. Paschou, Pauls, Mathews, and Scharf. This study was also funded in part by NIH grants R01MH092290 to Dr. Brown, R01MH092291 to Dr. Kuperman, R01MH092292 to Dr. Coffey, R01MH092293 to Dr. Heiman, R01MH092513 to Dr. Zinner, R01MH092516 to Dr. Grice, R01MH092520 to Dr. Gilbert, R01MH092289 to Dr. State, P01AG021654 and the Nathan Shock Center of Excellence for the Biology of Aging P30AG038072 to Dr. Barzilai, and R01AG042188 to Dr. Atzmon, as well as a grant from the German Research Society to Dr. Hebebrand. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment, and Health Initiative [GEI] (U01 HG004422); SAGE is one of the genomewide association studies funded as part of the Gene Environment Association Studies (GENEVA) under the NIH GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of data sets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392), and the Family Study of Cocaine Dependence (R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, NIDA, and the NIH contract “High Throughput Genotyping for Studying the Genetic Contributions to Human Disease” (HHSN268200782096C). The data sets used for the analyses described here were obtained from dbGaP (http://www.ncbi.nlm. nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000092.v1.p1) through dbGaP accession number phs000092.v1.p. Funding Information: Supported by NIH grants U01 NS040024 to Drs. Pauls, Mathews, and Scharf and the Tourette Association of America International Consortium for Genetics, NIH grants K23 MH085057 and K02 NS085048 and ARRA grant NS040024-09S1 to Dr. Scharf, NIH grant NS016648 and ARRA grant NS040024-07S1 to Dr. Pauls, grant MH096767 to Dr. Mathews, National Institute of Neurological Disorders and Stroke (NINDS) Informatics Center for Neurogenetics and Neurogenomics grant P30 NS062691 to Drs. Coppola and Freimer, and grants from the Tourette Association of America to Drs. Paschou, Pauls, Mathews, and Scharf. This study was also funded in part by NIH grants R01MH092290 to Dr. Brown, R01MH092291 to Dr. Kuperman, R01MH092292 to Dr. Coffey, R01MH092293 to Dr. Heiman, R01MH092513 to Dr. Zinner, R01MH092516 to Dr. Grice, R01MH092520 to Dr. Gilbert, R01MH092289 to Dr. State, P01AG021654 and the Nathan Shock Center of Excellence for the Biology of Aging P30AG038072 to Dr. Barzilai, and R01AG042188 to Dr. Atzmon, as well as a grant from the German Research Society to Dr. Hebebrand. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment, and Health Initiative [GEI] (U01 HG004422); SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under the NIH GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of data sets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392), and the Family Study of Cocaine Dependence (R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, NIDA, and the NIH contract “High Throughput Genotyping for Studying the Genetic Contributions to Human Disease” (HHSN268200782096C). The data sets used for the analyses described here were obtained from dbGaP (http://www.ncbi.nlm. Publisher Copyright: © 2019 American Psychiatric Association. All rights reserved.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Objective: Tourette's syndrome is polygenic and highly heritable. Genome-wide association study (GWAS) approaches are useful for interrogating the genetic architecture and determinants of Tourette's syndrome and other tic disorders. The authors conducted a GWAS meta-analysis and probed aggregated Tourette's syndrome polygenic risk to test whether Tourette's and related tic disorders have an underlying shared genetic etiology and whether Tourette's polygenic risk scores correlate with worst-ever tic severity and may represent a potential predictor of disease severity. Methods: GWAS meta-analysis, gene-based association, and genetic enrichment analyses were conducted in 4,819 Tourette's syndrome case subjects and 9,488 control subjects. Replication of top loci was conducted in an independent population-based sample (706 case subjects, 6,068 control subjects). Relationships between Tourette's polygenic risk scores (PRSs), other tic disorders, ascertainment, and tic severity were examined. Results: GWAS and gene-based analyses identified one genome-wide significant locus within FLT3 on chromosome 13, rs2504235, although this association was not replicated in the population-based sample. Genetic variants spanning evolutionarily conserved regions significantly explained 92.4% of Tourette's syndrome heritability. Tourette's-associated genes were significantly preferentially expressed in dorsolateral prefrontal cortex. Tourette's PRS significantly predicted both Tourette's syndrome and tic spectrum disorders status in the population-based sample. Tourette's PRS also significantly correlated with worst-ever tic severity and was higher in case subjects with a family history of tics than in simplex case subjects. Conclusions: Modulation of gene expression through noncoding variants, particularly within cortico-striatal circuits, is implicated as a fundamental mechanism in Tourette's syndrome pathogenesis. At a genetic level, tic disorders represent a continuous spectrum of disease, supporting the unification of Tourette's syndrome and other tic disorders in future diagnostic schemata. Tourette's PRSs derived from sufficiently large samples may be useful in the future for predicting conversion of transient tics to chronic tic disorders, as well as tic persistence and lifetime tic severity.
AB - Objective: Tourette's syndrome is polygenic and highly heritable. Genome-wide association study (GWAS) approaches are useful for interrogating the genetic architecture and determinants of Tourette's syndrome and other tic disorders. The authors conducted a GWAS meta-analysis and probed aggregated Tourette's syndrome polygenic risk to test whether Tourette's and related tic disorders have an underlying shared genetic etiology and whether Tourette's polygenic risk scores correlate with worst-ever tic severity and may represent a potential predictor of disease severity. Methods: GWAS meta-analysis, gene-based association, and genetic enrichment analyses were conducted in 4,819 Tourette's syndrome case subjects and 9,488 control subjects. Replication of top loci was conducted in an independent population-based sample (706 case subjects, 6,068 control subjects). Relationships between Tourette's polygenic risk scores (PRSs), other tic disorders, ascertainment, and tic severity were examined. Results: GWAS and gene-based analyses identified one genome-wide significant locus within FLT3 on chromosome 13, rs2504235, although this association was not replicated in the population-based sample. Genetic variants spanning evolutionarily conserved regions significantly explained 92.4% of Tourette's syndrome heritability. Tourette's-associated genes were significantly preferentially expressed in dorsolateral prefrontal cortex. Tourette's PRS significantly predicted both Tourette's syndrome and tic spectrum disorders status in the population-based sample. Tourette's PRS also significantly correlated with worst-ever tic severity and was higher in case subjects with a family history of tics than in simplex case subjects. Conclusions: Modulation of gene expression through noncoding variants, particularly within cortico-striatal circuits, is implicated as a fundamental mechanism in Tourette's syndrome pathogenesis. At a genetic level, tic disorders represent a continuous spectrum of disease, supporting the unification of Tourette's syndrome and other tic disorders in future diagnostic schemata. Tourette's PRSs derived from sufficiently large samples may be useful in the future for predicting conversion of transient tics to chronic tic disorders, as well as tic persistence and lifetime tic severity.
UR - http://www.scopus.com/inward/record.url?scp=85063063105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063063105&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2018.18070857
DO - 10.1176/appi.ajp.2018.18070857
M3 - Article
C2 - 30818990
AN - SCOPUS:85063063105
SN - 0002-953X
VL - 176
SP - 217
EP - 227
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 3
ER -